ArticleBreast cancer research and treatment2026
Clinicopathologic features, treatment patterns and survival outcomes of acinic cell carcinoma of the breast: a national cancer database analysis.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcinic cell carcinoma (ACC) of the breast is a rare malignancy characterized by serous acinar differentiation resembling salivary gland ACC. Although historically described as a triple-negative malignancy, its immunophenotypic profile and clinical behavior remain incompletely characterized. This study leverages a large national database to characterize the clinicopathologic features, treatment approaches, and survival outcomes of breast ACC.
methodsThe National Cancer Database (NCDB) was queried for patients with invasive breast ACC diagnosed between 2004 and 2023. Overall survival (OS) was assessed using Kaplan-Meier analysis and compared with log-rank tests. Multivariable Cox regression analysis was used to evaluate independent associations with OS.
resultsA total of 149 patients with breast ACC were identified. Mean age was 57.8 ± 14.3 years, and median tumor size was 2.0 cm. Most patients presented with early-stage disease (Stage I-II, 86.7%). 44.6% demonstrated poorly differentiated or anaplastic tumors. Node-positive disease was present in 27.0% of patients. Hormone receptor expression was common (ER 57.1%, PR 50.7%), while 93.5% were HER2-negative. The 5-year OS was 82.9%. Older age (p < 0.001), advanced stage (p < 0.001), and nodal positivity (p = 0.038) were associated with worse OS. Surgical resection was associated with improved survival (p < 0.001), while radiation, chemotherapy and hormonal therapy were not associated with OS. On multivariable analysis, surgical resection remained independently associated with survival (HR 0.03, 95% CI 0.005-0.25, p < 0.001).
conclusionsBreast ACC presents at an early stage with hormone receptor heterogeneity. Surgical resection was the only modality independently associated with improved survival.
Indexed as
Identifiers
42446757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.